Skip to main content

Table 10 The scores of SF-36 in the 24-month period

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group

\( \overline{x}\pm S \)

t

P

The treatment group

67.72 ± 6.06

−0.397

0.691

The control group

67.47 ± 5.53

  
Back to article page

Trials

ISSN: 1745-6215